Nivalis Therapeutics

Nivalis Therapeutics, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of product candidates for patients with cystic fibrosis (CF). CF is a life-shortening genetic disease. Its lead product candidate is N91115, a small molecule that is in Phase II clinical trial, which addresses a defect in cystic fibrosis transmembrane conductance regulator (CFTR), resulting from mutations in the CFTR gene. The company was formerly known as N30 Pharmaceuticals, Inc. and changed its name to Nivalis Therapeutics, Inc. in February 2015. Nivalis Therapeutics, Inc. was founded in 2007 and is headquartered in Boulder, Colorado.
Type
Public
HQ
Boulder, US
Founded
2007
Size (employees)
29 (est)
Nivalis Therapeutics was founded in 2007 and is headquartered in Boulder, US

Nivalis Therapeutics Office Locations

Nivalis Therapeutics has an office in Boulder
Boulder, US (HQ)
200 3122 Sterling Dr

Nivalis Therapeutics Data and Metrics

Nivalis Therapeutics Financial Metrics

Numbers are in $, USD

Net income (FY, 2016)

(31.5 m)

Market capitalization (26-May-2017)

36.6 m

Closing share price (26-May-2017)

2.4

Cash (31-Dec-2016)

24.2 m
Nivalis Therapeutics's current market capitalization is $36.6 m.
Numbers are in $, USDFY, 2015FY, 2016

Net Income

(22.8 m)(31.5 m)
Numbers are in $, USDFY, 2015FY, 2016

Cash

25 m24.2 m

Inventories

432 k628 k

Current Assets

87.7 m61.7 m

Total Assets

87.9 m61.9 m

Accounts Payable

994 k1.9 m

Current Liabilities

4.4 m6.5 m

Additional Paid-in Capital

232.3 m235.7 m

Retained Earnings

(148.8 m)(180.3 m)

Total Equity

83.5 m55.4 m

Financial Leverage

1.1 x1.1 x
Numbers are in $, USDFY, 2015FY, 2016

Net Income

(22.8 m)(31.5 m)

Accounts Payable

65 k927 k

Cash From Operating Activities

(19.2 m)(26.3 m)

Purchases of PP&E

(188 k)(106 k)

Cash From Investing Activities

(62.4 m)25.3 m

Cash From Financing Activities

78.8 m166 k

Interest Paid

165 k165 k
Y, 2016

Financial Leverage

1.1 x

Nivalis Therapeutics Operating Metrics

FY, 2016

Patents Issued

245

Patent Applications

42

Patents Licensed

12

Nivalis Therapeutics Market Value History

Nivalis Therapeutics Online and Social Media Presence

Nivalis Therapeutics Company Life and Culture

You may also be interested in